Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T22:50:20.888Z.
Calculation as of: 2026-10-06T22:50:20.888Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5c9508078213b28dfeff6809371853141f28b2786ea2d18fc4f82dd6840af9a4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Advanced Biomed Inc. Common Stock
Market Cap
$8.82M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Advanced Biomed Inc. Common Stock (ADVB) | $8.82M | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.05M | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.10M | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.14M | N/A |
| Ainos, Inc. (AIMD)vs › | $9.50M | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.05M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.04M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | N/A |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
